Brief: Abbisko Cayman Says Csf-1R Inhibitor, Pimicotinib (Absk021) Approved By Nmpa For Phase Ii Clinical Study
17/01/2023 24:08
Jan 17 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR, PIMICOTINIB (ABSK021) APPROVED BY
CHINA'S NMPA
FOR A PHASE II CLINICAL STUDY
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly